| Company Name | Bayer Taiwan Co., Ltd |
|---|---|
| Protocol Number | 21460 |
| Title of Study | Systemic treatment patterns of hepatocellular carcinoma (HCC) in Taiwan |
| Primary Objective | The primary objective is to describe systemic treatment patterns of unresectable HCC patients in Taiwan whose first-line systemic treatment is sorafenib. |
| Number of Sites | 1 |
| Period of Study | From： to： |
| Number of Patients | 415人 |
| IRB Approval Date | 2020/08/15 |
| Publication Plan / Date | 2022/12/31 |
